国际肿瘤学杂志

国际肿瘤学杂志 ›› 2019, Vol. 46 ›› Issue (2): 94-97.doi: 10.3760/cma.j.issn.1673-422X.2019.02.007

• 综述 • 上一篇    下一篇

头颈部鳞状细胞癌的内科治疗

柴玥,董梅   

  1. 国家癌症中心 国家肿瘤临床医学研究中心 中国医学科学院 北京协和医学院肿瘤医院内科, 北京100021
  • 出版日期:2019-02-08 发布日期:2019-04-03
  • 通讯作者: 董梅，Email： dongmei030224@163.com E-mail:dongmei030224@163.com

Medical treatment in head and neck squamous cell carcinoma

Chai Yue, Dong Mei   

  1. National Cancer Center, National Clinical Research Center for Cancer; Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
  • Online:2019-02-08 Published:2019-04-03
  • Contact: Dong Mei, Email： dongmei030224@163.com E-mail:dongmei030224@163.com

PDF

617

摘要： 内科治疗是头颈部鳞状细胞癌的重要治疗手段，研究表明对于局部晚期头颈部鳞状细胞癌患者，3周顺铂方案可作为首选方案，而对于复发或转移的头颈部鳞状细胞癌患者，西妥昔单抗联合铂类药物及5氟尿嘧啶可作为一线化疗方案。部分研究显示免疫治疗可延长复发或转移头颈鳞状细胞癌患者的生存期，且安全性和耐受性良好，正逐渐成为肿瘤的第四大治疗手段。目前依然没有充分证据表明头颈部鳞状细胞癌患者能从诱导化疗中获益，有待于进一步探索。

关键词: 头颈部肿瘤, 肿瘤, 鳞状细胞, 药物疗法

Abstract: Medical treatment is an important strategy for patients with head and neck squamous cell carcinoma (HNSCC). Studies have shown that threeweekly cisplatin regimen is a promising treatment for patients with locally advanced HNSCC and cetuximab plus platinum and 5fluorouracil can be the firstline therapy for patients with recurrent or metastatic HNSCC. Current results from immunotherapy trials have shown an improved response rate and overall survival in patients with recurrent or metastatic HNSCC while maintaining a safe and tolerable toxicity profile. Immunotherapy is becoming the fourth treatment strategy towards cancer. There is still insufficient evidence that patients with HNSCC can benefit from induction chemotherapy and further study is warranted.

Key words: Head and neck neoplasms, Neoplasms, squamous cell, Drug therapy